Edward Holson

Edward Holson is a distinguished scientific leader with extensive experience in the biotechnology and pharmaceutical sectors. Currently serving as Chief Scientific Officer and President of the US division at Anavo Therapeutics BV since 2024, Edward also contributes to the Ara Parseghian Medical Research Fund as a member of the Scientific Advisory Board and holds multiple board positions, including at KDAc Therapeutics and Amathus Therapeutics, where Edward is a co-founder and has held roles such as President and Chief Scientific Officer. Previous positions include co-founding Photys Therapeutics and serving as Venture Advisor at Longwood Fund. Edward’s earlier career features significant roles at the Broad Institute of MIT and Harvard, and Infinity Pharmaceuticals, with expertise in medicinal chemistry and pharmaceutical development. Edward earned a Bachelor of Arts in Biochemistry from The University of Texas at Austin and a PhD in Organic Chemistry from the University of Michigan.